Froesch, Patrizia

Mark, Michael; Froesch, Patrizia; Gysel, Katrin; Rothschild, Sacha I; Addeo, Alfredo; Ackermann, Christoph J; Chiquet, Sabrina; Schneider, Martina; Ribi, Karin; Maranta, Angela Fischer; Bastian, Sara; von Moos, Roger; Joerger, Markus; Früh, Martin (2024). First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17. European journal of cancer, 200(113600), p. 113600. Elsevier 10.1016/j.ejca.2024.113600

Rothschild, Sacha I; Zippelius, Alfred; Eboulet, Eric I; Savic Prince, Spasenija; Betticher, Daniel; Bettini, Adrienne; Früh, Martin; Joerger, Markus; Lardinois, Didier; Gelpke, Hans; Mauti, Laetitia A; Britschgi, Christian; Weder, Walter; Peters, Solange; Mark, Michael; Cathomas, Richard; Ochsenbein, Adrian F; Janthur, Wolf-Dieter; Waibel, Christine; Mach, Nicolas; ... (2021). SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial. Journal of clinical oncology, 39(26), pp. 2872-2880. American Society of Clinical Oncology 10.1200/JCO.21.00276

Froesch, Patrizia; Mark, Michael; Rothschild, Sacha I; Li, Qiyu; Godar, Gilles; Rusterholz, Corinne; Oppliger Leibundgut, Elisabeth; Schmid, Sabine; Colombo, Ilaria; Metaxas, Yannis; König, David; Sessa, Cristiana; Gautschi, Oliver; Früh, Martin (2021). Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial. Lung cancer, 156, pp. 91-99. Elsevier 10.1016/j.lungcan.2021.04.002

Gautschi, Oliver; Rothschild, Sacha I; Li, Qiyu; Matter-Walstra, Klazien; Zippelius, Alfred; Betticher, Daniel C; Früh, Martin; Stahel, Rolf A; Cathomas, Richard; Rauch, Daniel; Pless, Miklos; Peters, Solange; Froesch, Patrizia; Zander, Thilo; Schneider, Martina; Biaggi, Christine; Mach, Nicolas; Ochsenbein, Adrian (2017). Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. Clinical lung cancer, 18(3), pp. 303-309. Elsevier 10.1016/j.cllc.2016.11.007

Zappa, Francesco; Droege, Cornelia; Betticher, Daniel; von Moos, Roger; Bubendorf, Lukas; Ochsenbein, Adrian; Gautschi, Oliver; Oppliger Leibundgut, Elisabeth; Froesch, Patrizia; Stahel, Rolf; Hess, Thomas; Rauch, Daniel; Schmid, Petra; Mayer, Michael; Crowe, Susanne; Brauchli, Peter; Ribi, Karin; Pless, Miklos; on behalf of the Swiss Group for Clinical Cancer Research (SAKK), (2012). Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05). Lung cancer, 78(3), pp. 239-44. Amsterdam: Elsevier 10.1016/S1359-6349(09)71860-9